• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

BMJ Rapid Recommendations on use of proprotein convertase subtilisin/kexin 9 inhibitors and ezetimibe to reduce cardiovascular risk
The new BMJ Rapid Recommendations addressed the following question: should we add another lipid-lowering drug in adults with low-density lipoprotein-cholesterol (LDL-C) over 1.8 mmol/L using a maximal dose of statins or intolerant to statins?1 Why is this question important? Both proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and ezetimibe have been shown to reduce LDL-C by approximately 60% and approximately 20%, respectively, and correspondingly may reduce major adverse cardiovascular events (MACE), including all-cause death, cardiovascular death, myocardial infarction (MI) and stroke. However, the bene...
Source: Heart - July 27, 2022 Category: Cardiology Authors: White, H. D. Tags: Editorials Source Type: research

Sex differences in cardiovascular outcome during progression of aortic valve stenosis
Conclusions In the SEAS study, women and men had similar rates of AS progression and AS-related events. However, women had lower total mortality and ischaemic CV event rate than men independent of confounders. Trial registration number ClinicalTrials.gov identifier: NCT00092677.
Source: Heart - January 14, 2015 Category: Cardiology Authors: Cramariuc, D., Rogge, B. P., Lonnebakken, M. T., Boman, K., Bahlmann, E., Gohlke-Barwolf, C., Chambers, J. B., Pedersen, T. R., Gerdts, E. Tags: Open access, Drugs: cardiovascular system, Echocardiography, Hypertension, Interventional cardiology, Aortic valve disease, Clinical diagnostic tests, Epidemiology Valvular heart disease Source Type: research

Cardiovascular highlights from non-cardiology journals
Niacin fails to prevent cardiovascular events Observational studies have consistently demonstrated that levels of LDL cholesterol directly correlate with cardiovascular risk while HDL levels are inversely related to cardiovascular risk. Niacin is known to reduce LDL levels and concurrently raise HDL levels. In the HPS2-THRIVE study, 25,673 patients with a background of vascular disease were randomized to receive 2 g of extended-release niacin and 40 mg of laropiprant (an anti-flushing agent) or a matching placebo daily. Prior to starting the study, in a run-in phase, background statin therapy was standardized wit...
Source: Heart - September 23, 2014 Category: Cardiology Authors: Bradley, S. M. Tags: Journal scan Source Type: research